1Chandler WL.A kinetic model of the circulatory regulation of tissue plasimnogen activator[J].Thromb Haemost,2005,66:321 -328
2Di Minno G,Mancini FP,Margaglione M.Hemostatic variables and ischemic cardiovascular disease:do we need a concerted effort for more profitable future clinical investigations?[J].Cardiovasc Drugs Ther,2003,10:743-749
3Mansfield MW,Stickland MH,Grant PJ.PAI-1 concentrations in first degree relatives of patients with non-insulin dependent diabetes:metabolic and genetic associations[J].Thromb Haemost,2004,77:357-361
4Margaglione M,Grandone E,Vecchiong G,et al.Plasrninogen activator inhibitor-lantigen plasma levels in subjects attending a metabolic ward:relation to polymorphisms of the PAI-1 and of the angiotensin converting enzyme genes[J].Arterioscler Thromb Vasc biol,2004,17:2082-2087
5Follo M,Ginsburg D.Structure and expression of the human gene encoding plasminogen activator inhibitor,PAl-1[J].Gene,2003,84:447-453
6Smith EB.Haemostatic factors and atherogenesis[J].Athersclerosis,2007,124:137-143
7Koenig W.Haemostatic risk factors for cardiovascular diseases[J].Eur Heart J,2006,19:C39-43
9Eriksson P,Nilsson L,Karpe F,et al.Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia[J].Arterioscler Thromb Vasc Bid,2006,18:20-26
10Dawson SJ,Wiman B,Hamsten A,et al.The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 gene respond differently to interlerkin-1 in HepG2 cells[J].J Biol Chem,268:10739-10745
